Your new post is loading...
Lung cancer uses cunning mechanisms to evade the immune system. Can new antibody therapies outwit the disease?
Via Krishan Maggon
|
Rescooped by Gilbert C FAURE from Cancer Immunotherapy Review and Collection |
Scoop.it!
Via Krishan Maggon
After 20 years of treating lung cancer, and 20 years of dashed hopes in lung-cancer immunotherapy, there is finally a glimmer of hope in both vaccines and non-vaccine immunotherapies, such as the PD-1 and PD-L1 inhibitors.
If the past decades of failure have taught the industry anything, it is that early trial success rarely leads to a breakthrough drug. Phase III trial data from the checkpoint inhibitors and the vaccines are eagerly awaited.
Open access
NATURE | OUTLOOK
Immunotherapy: Chemical tricksBianca NogradyNature 513, S10–S11 (11 September 2014) doi:10.1038/513S10aPublished online 10 September 2014